Older Age and Complex Karyotype Are the Main Predictors of Mortality Irrespective of Transplantation in Therapy‐Related Myeloid Neoplasms
- 28 October 2026
- journal article
- Published by Wiley in European Journal of Haematology
Abstract
Therapy‐related myeloid neoplasms (t‐MN) are late complications of cancer therapies. We retrospectively analyzed 86 adults diagnosed from 2007 to 2025 with t‐MN (acute myeloid leukemia [AML] n = 31, myelodysplastic neoplasms [MDS] n = 38, MDS/AML n = 17). We estimated overall survival (OS) and cumulative incidence of disease related mortality (DRM). Uni‐ and multivariable models identified predictors of mortality; interaction models defined the role of allogeneic hemopoietic stem cell transplantation (allo‐HSCT) in elderly patients and complex karyotype (CK) t‐MN. Median age at diagnosis was 65.5 years, previous cancer was solid in 29% or hematologic in 71%. Among 66/86 candidates to active therapy, 39/66 were candidates to allo‐HSCT and 24 received it. In our cohort, we had demonstrated a high prevalence of adverse baseline genomics (47% of CK) and poor OS (11.94 months), partially mitigated by allo‐HSCT (29.47 vs. 9.01 months, p = 0.028). In univariable and multivariable analysis, age ≥ 65 years and CK but not allo‐HSCT were DRM predictors. In interaction models, age ≥ 65 years remained deleterious regardless of transplant whereas allo‐HSCT could offset CK‐related risk, supporting transplantation even in high‐risk cytogenetics, when disease control and fitness criteria are met. Overall, t‐MN remained highly lethal, with DRM primarily driven by age and CK; allo‐HSCT attenuated cytogenetic risk.Keywords
This publication has 19 references indexed in Scilit:
- Outcomes of therapy‐related non‐core binding factor acute myeloid leukemia with venetoclax‐based therapiesHemaSphere, 2026
- Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2024
- Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in AdultsTransplantation and Cellular Therapy, 2021
- Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern EraJAMA Oncology, 2019
- Therapy-related myeloid neoplasms: when genetics and environment collideNature Reviews Cancer, 2017
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016
- Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy‐related leukemiaCancer, 2015
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015
- Characteristics and outcome of therapy‐related myeloid neoplasms: Report from the Italian network on secondary leukemiasAmerican Journal of Hematology, 2015
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemiaNature, 2014